ClinicalTrials.Veeva

Menu

Optical Coherence Tomography for Intracranial Atherosclerotic Stenosis (OCT-ICAS)

J

jiaoliqun

Status

Enrolling

Conditions

Optical Coherence Tomography
Ischemic Stroke
Intracranial Atherosclerosis
Artery Stenosis
Plaque, Atherosclerotic

Treatments

Procedure: Percutaneous transluminal angioplasty and stenting
Diagnostic Test: Optical Coherence Tomography

Study type

Observational

Funder types

Other

Identifiers

NCT05550077
OCT-ICAS

Details and patient eligibility

About

To evaluate the clinical significance of optical coherence tomography (OCT) in interventional treatment of intracranial atherosclerotic stenosis (ICAS).

Full description

Stroke was the second leading cause of death worldwide and the leading cause of death in China in 2017. ICAS accounted for 10% to 15% of ischemic stroke in Western countries, and as much as 46.6%in Asia in 2009.

For patients with ICAS, the risk of stroke is highly related to the histopathology of atheromatous plaques. Therefore, characterizing the morphology and composition of plaques in ICAS may help to predict the risk of stroke occurrence and allow the adoption of preventive or therapeutic management to prevent such life-threatening events. OCT, with a resolution of 10μm, may provide more reliable information in characterizing atheromatous plagues.

This study aims to get a better insight into the value of OCT in evaluating the vessel wall structure and therefore guiding the interventional therapy of ICAS. In addition, the clinical and biological information will be included to achieve correlation analysis so as to get biomarkers subject to various plaque characteristics.

Enrollment

400 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Symptomatic ICAS. Participants with ICAS with a transient ischaemic attack (TIA) or stroke attributable to the territory of the stenotic artery were defined as symptomatic. A TIA was defined as a transient episode of neurological dysfunction (focal weakness or language disturbance, transient monocular blindness, or required assistance in walking) caused by focal brain or retinal ischaemia that lasted for at least 10 minutes but resolved within 24 hours
  • Stenotic degree ≥ 50%, measured by digital subtraction angiography
  • The stenosis must located in at least one major intracranial artery (internal carotid artery, vertebral artery, middle cerebral artery, or basilar artery)

Exclusion criteria

  • Arteriovenous Malformation
  • Aneurysm

Trial design

400 participants in 2 patient groups

Optical Coherence Tomography (OCT)
Description:
OCT and other classical imaging evaluation such as Transcranial Color Doppler (TCCD) and High resolution-MRI will be performed. The tailored treatment (such as anti-thrombotic management, post-dilation, et al) will be considered when specific plaque characteristics (including but not limited to in situ thrombus formation, macrocacilfication, et al), were observed under OCT.
Treatment:
Procedure: Percutaneous transluminal angioplasty and stenting
Diagnostic Test: Optical Coherence Tomography
Non-Optical Coherence Tomography (N-OCT)
Description:
Classical imaging evaluation such as TCCD and High resolution-MRI will be performed, followed by standard percutaneous transluminal angioplasty and stenting.
Treatment:
Procedure: Percutaneous transluminal angioplasty and stenting

Trial contacts and locations

1

Loading...

Central trial contact

Liqun Jiao, Professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems